+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Precision Medicine market set to grow to $97bn by 2024” says new Visiongain report

30 May 2019
Pharma

Visiongain has launched a new pharma report Global Precision Medicine Market Forecast 2019-2029: Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular Diseases, Central Nervous System, Infectious Diseases.

The global precision medicine market is expected to grow at an estimated CAGR of 10.5% from 2018 to 2029. In the precision medicine market, the Diagnostic Tool companies segment is dominating the global market and accounted for $23.36 billion in 2018 due to the development of large number of diagnostic and genetic tests.

The lead analyst of the report commented "The deep understanding of precision medicine applications within the context of e-Health will be essential to align the benefits of mobile technologies within the broader framework of health and e-Health priorities. Faulty regulations for healthcare providers is affecting the precision medicine market as they are hampering the innovation and technological developments.

One of the reasons for the hampered growth of the precision medicine market is the lack of knowledge and awareness about the possible applications of precision medicine application and public health outcomes among the end users. This challenge highlighted the need for evaluation of precision medicine related educational programs across a range of target groups."

Leading companies featured in the report include Abbott, Danaher Corporation, GE Healthcare, GlaxoSmithKline, Illumina, Inc., Johnson & Johnson, Laboratory Corporation of America Holdings and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on + 44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read